CFWCX
Price
$27.32
Change
+$0.13 (+0.48%)
Updated
Jun 2 closing price
Net Assets
552.11M
FSDPX
Price
$103.92
Change
+$1.61 (+1.57%)
Updated
Jun 2 closing price
Net Assets
823.57M
Interact to see
Advertisement

CFWCX vs FSDPX

Header iconCFWCX vs FSDPX Comparison
Open Charts CFWCX vs FSDPXBanner chart's image
CFWCX vs FSDPX Comparison Chart in %
View a ticker or compare two or three
VS
CFWCX vs. FSDPX commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CFWCX is a Buy and FSDPX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
FSDPX has more cash in the bank: 824M vs. CFWCX (552M). FSDPX pays higher dividends than CFWCX: FSDPX (1.30) vs CFWCX (0.26). CFWCX was incepted earlier than FSDPX: CFWCX (18 years) vs FSDPX (40 years). CFWCX (2.04) is less costly to investors than FSDPX (0.69). FSDPX is a more actively managed with annual turnover of: 56.00 vs. CFWCX (24.00). FSDPX has a lower initial minimum investment than CFWCX: FSDPX (0) vs CFWCX (1000). FSDPX annual gain was more profitable for investors over the last year : 17.50 vs. CFWCX (4.94). CFWCX return over 5 years is better than : 5.22 vs. FSDPX (4.75).
CFWCXFSDPXCFWCX / FSDPX
Total Expense Ratio1.990.69288%
Annual Report Gross Expense Ratio2.040.69296%
Fund Existence18 years40 years-
Gain YTD2.60411.67822%
Front LoadN/AN/A-
Min. Initial Investment10000-
Min. Initial Investment IRAN/AN/A-
Net Assets552M824M67%
Annual Yield % from dividends0.261.3020%
Returns for 1 year4.9417.5028%
Returns for 3 years12.7414.7486%
Returns for 5 years5.224.75110%
Returns for 10 years79.5049.54160%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
USAU15.810.01
+0.06%
US Gold Corp
YOU56.78-0.65
-1.13%
Clear Secure
SKYE0.72-0.04
-5.42%
Skye Bioscience
SNOW261.14-19.02
-6.79%
Snowflake
MPLT27.34-2.42
-8.13%
MapLight Therapeutics Inc.